Aclaris Therapeutics, Inc. ACRS · Stock Open Aclaris Therapeutics, Inc. in new tab
Aclaris Therapeutics, Inc. Analysis (ACRS)
Is Aclaris Therapeutics, Inc. a good investment? Aclaris Therapeutics, Inc. (ACRS) is currently trading at 5.68 USD. Market analysts have a consensus price target of 10.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Aclaris Therapeutics, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.83.
Investor FAQ
Does Aclaris Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Aclaris Therapeutics, Inc.?
Aclaris Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -0.56.
Company Profile
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Community Discussion